- Trials with a EudraCT protocol (39)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
39 result(s) found for: Innate Immune Cells.
Displaying page 1 of 2.
EudraCT Number: 2021-004573-32 | Sponsor Protocol Number: 21-05 | Start Date*: 2021-10-05 |
Sponsor Name:Centre Hospitalier Annecy Genevois | ||
Full Title: Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) versus Standard-Dose (QIV-SD), in subjects 65 years of age and older on innate immunity, including gene expression. | ||
Medical condition: Healthy volunteers (influenza vaccination) | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-003325-22 | Sponsor Protocol Number: 2022-15944 | Start Date*: 2023-01-25 |
Sponsor Name:RadboudUMC | ||
Full Title: The immunomodulatory effect of sugammadex after total hip replacement surgery under neuraxial anaesthesia: a pilot study | ||
Medical condition: Hip osteoarthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-001952-32 | Sponsor Protocol Number: ACA-NETH-07-14 | Start Date*: 2008-11-07 |
Sponsor Name:Radboud University Nijmegen Medical Centre - Department of Dermatology | ||
Full Title: The effect of adalimumab on immune markers in lesional psoriatic skin. | ||
Medical condition: Plaque psoriasis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-005860-24 | Sponsor Protocol Number: OmniaOMS | Start Date*: 2022-10-28 | |||||||||||
Sponsor Name:I.R.C.C.S. FONDAZIONE S.LUCIA | |||||||||||||
Full Title: Multidimensional integrated assessment of neurological and immunological patterns to test the efficacy and response to Ozanimod in multiple sclerosis | |||||||||||||
Medical condition: relapsing remitting multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005174-11 | Sponsor Protocol Number: U1111-1166-6923 | Start Date*: 2015-10-01 |
Sponsor Name:Uppsala University Hospital | ||
Full Title: A randomized, double-blinded placebo-controlled, paralleled designed, investigator sponsored study of the effect of the GLP-1 receptor agonist liraglutide on beta-cell function in C-peptide positiv... | ||
Medical condition: Beta-cell function in C-peptide positive type 1 diabetes | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-001450-22 | Sponsor Protocol Number: MESCEL-COVID19 | Start Date*: 2020-04-29 | |||||||||||
Sponsor Name:Fundación de Investigación del Hospital Infantil Universitario Niño Jesús | |||||||||||||
Full Title: Phase II Clinical Trial to explore the efficacy of allogeneic mesenchymal cells from umbilical cord tissue in patients with severe pulmonary involvement by COVID-19. | |||||||||||||
Medical condition: Severe pulmonary involvement by COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004961-14 | Sponsor Protocol Number: UV2013/4 | Start Date*: 2014-06-11 | |||||||||||
Sponsor Name:Kliniken Kärnan Urology Centre | |||||||||||||
Full Title: Pilot study to investigate the mode of action (MoA) of Uro-Vaxom® on a molecular level in pre-menopausal women suffering from recurrent urinary tract infections (rUTI) | |||||||||||||
Medical condition: Recurrent urinary tract infections (rUTI) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000116-42 | Sponsor Protocol Number: BioVacSafe-QIV | Start Date*: 2017-03-02 | |||||||||||
Sponsor Name:Ghent University Hospital | |||||||||||||
Full Title: A clinical study of biomarkers of innate and adaptive immune activation associated with symptoms and immune responses after administration of a single dose of a quadrivalent inactivated split virus... | |||||||||||||
Medical condition: Healthy Volunteers - a quadrivalent inactivated split virus influenza vaccine | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003543-35 | Sponsor Protocol Number: BioVacSafe–FluadTM | Start Date*: 2014-09-23 | |||||||||||
Sponsor Name:Ghent University Hospital | |||||||||||||
Full Title: A clinical study to generate a set of data characterising clinical events, physiological responses, and innate and adaptive immune responses following a single intramuscular immunisation with Fluad... | |||||||||||||
Medical condition: vaccin against influenza | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000685-42 | Sponsor Protocol Number: 2DR-study | Start Date*: 2020-04-30 |
Sponsor Name:Ghent University Hospital | ||
Full Title: Virological and immunological assessment in HIV positive participants on 2DR versus 3DR in a prospective randomized controlled switch trial. | ||
Medical condition: human immunodeficiency viruses (HIV) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002808-25 | Sponsor Protocol Number: AI444-281 | Start Date*: 2015-04-16 |
Sponsor Name:Academic Medical Center Amsterdam | ||
Full Title: Immune phenotyping in chronic hepatitis C patients treated with Sofosbuvir and Daclatasvir combination with or without Ribavirin for 12 or 24 weeks -SODA study | ||
Medical condition: Chronic hepatitis C | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-005520-42 | Sponsor Protocol Number: BCG-LPS | Start Date*: 2014-04-28 | |||||||||||
Sponsor Name:Radboud University Nijmegen Medical Centre | |||||||||||||
Full Title: The effects of BCG-vaccination on the innate immune response and immunoparalysis in healthy volunteers | |||||||||||||
Medical condition: sepsis induced immunoparalysis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021221-12 | Sponsor Protocol Number: UMC Utrecht | Start Date*: 2011-07-11 | |||||||||||
Sponsor Name:UMCU | |||||||||||||
Full Title: A phase I/ II study Efficacy and safety of alpha/beta T- /CD19B-cell depleted allogeneic haematopoietic stem cells transplantation in high risk or relapsed acute leukaemia / MDS followed by an inn... | |||||||||||||
Medical condition: Patients with high risk acute leukemia / MDS or relapse acute leukemia /MDS | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004567-11 | Sponsor Protocol Number: 75911 | Start Date*: 2020-12-08 | |||||||||||
Sponsor Name:Zealand University Hospital | |||||||||||||
Full Title: Effect of Low-dose Interferon-alfa2a on peri operative immune suppression | |||||||||||||
Medical condition: pMMR Colon cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002879-14 | Sponsor Protocol Number: BioVacSafe-Boostrix® | Start Date*: 2015-07-30 | |||||||||||
Sponsor Name:Ghent University Hospital | |||||||||||||
Full Title: BioVacSafe-Boostrix®: een klinische studie om een reeks gegevens te regenereren die kenmerkend zijn voor klinische gebeurtenissen, fysiologische reacties en aangeboren en adaptieve immuunreacties v... | |||||||||||||
Medical condition: vaccin against diphtheria, tetanus and pertussis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005141-20 | Sponsor Protocol Number: | Start Date*: 2013-02-27 | ||||||||||||||||
Sponsor Name:Royal Liverpool University Hospital [...] | ||||||||||||||||||
Full Title: FULL TITLE: Pneumococcal Conjugate Vaccine (PCV-13) and Experimental Human Pneumococcal Carriage Study (EHPC) Study. KEY WORDS: mucosa, innate, cellular, humoral, Streptococcus pneumoniae, pneumoco... | ||||||||||||||||||
Medical condition: Pneumococcal disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-022627-29 | Sponsor Protocol Number: IIR-HBV-2010 | Start Date*: 2011-03-29 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: Innate immune responses in patients with chronic hepatitis B treated with Sebivo (telbivudine) | |||||||||||||
Medical condition: Chronic HBV | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004376-18 | Sponsor Protocol Number: ANRSHB07 | Start Date*: 2021-06-10 | |||||||||||
Sponsor Name:Inserm ANRS | |||||||||||||
Full Title: ANRS HB07 IP-cure-B proof of concept (PoC) clinical trial. Educating the liver immune environment through TLR8 stimulation followed by NUC discontinuation | |||||||||||||
Medical condition: Chronic Hepatitis B virus (HBV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) ES (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002837-48 | Sponsor Protocol Number: HEAL-1-v1.5 | Start Date*: 2017-12-22 |
Sponsor Name:Erasmus MC | ||
Full Title: HIV Eradication by combining Agents to reverse Latency in vivo (HEAL-1): a randomized controlled trial. | ||
Medical condition: Adults with human immunodeficiency virus type-1 infection on antiretroviral treatment with adequate viral suppression and good cellular immunity. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001474-29 | Sponsor Protocol Number: SAINT | Start Date*: 2020-05-07 | |||||||||||
Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra | |||||||||||||
Full Title: Pilot study to evaluate the potential of ivermectin to reduce COVID-19 transmission | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.